HIV overcomes CRISPR gene-editing attack
By Ewen Callaway,
Nature
| 04. 07. 2016
HIV can defeat efforts to cripple it with CRISPR gene-editing technology, researchers say. And the very act of editing — involving snipping at the virus’s genome — may introduce mutations that help it to resist attack.
At least half a dozen papers over the past three years have explored using the popular CRISPR-Cas9 gene editing technique to combat HIV, but the latest finding, described in a study published on 7 April in Cell Reports (1), adds to questions about the feasibility of the approach. However, the researchers involved say that the discovery is a minor setback that does not preclude the idea altogether.
Some researchers aim to edit genes made by the immune cells that HIV usually infects — called T helper cells — so that the virus cannot find a way in. Others take a different tack: equipping the T cells with gene-editing tools so that they can seek and destroy any HIV that infects them.
This approach seemed simple and efficient in tissue culture, says Bryan Cullen, a virologist at Duke University in Durham, North Carolina, who has...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...